FDA Accepts for Review Resubmitted NDA for TransCon PTH (Pal

– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adult patients with hypoparathyroidism. The agency considered the resubmission a complete, class 2 response and set a Prescription Drug User Fee Act (PDUFA) goal date of May 14

Related Keywords

United States , Denmark , Redwood City , California , New Jersey , Copenhagen , Køavn , Heidelberg , Baden Wüberg , Germany , Munich , Bayern , Jan Mikkelsen , Ascendis Pharma , Us Food Drug Administration , Drug Administration , New Drug Application , Prescription Drug User Fee Act , Palo Alto , Forward Looking Statements , Hypoparathyroidism , Fda , Adult Patients , Transcon , Pdufa ,